More so than any other core function of the biopharma industry, clinical trials have been buffeted by the prevailing winds of the pandemic.
From the turbulent waves of infection causing overstretched healthcare facilities, inaccessible sites and patient availability through to the relative plain sailing of mammoth Phase III vaccine trials, COVID-19 has permanently changed the nature of clinical research.
This session explores the negative and positive aspects that the clinical trial ecosystem has either endured or capitalized upon, and attempts to answer the question as to whether we have emerged from the storm in a stronger position than before.
The presentation will touch upon topics such as:
- disruption to ongoing and planned trials
- patient engagement in clinical research
- digital and technology acceleration
- sponsor strategies and dynamics
Date: Wednesday, June 15th 2022
Time: 9:00 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
|9:00||Networking, registration and light breakfast|
David Munis Zepernick, Head of Member Engagement and Communication, Medicon Valley Alliance
|9:35||Pharma Intelligence Introduction|
Alex Harris, Northern Europe & Israel Commercial Lead, Pharma Intelligence
|9:40||Measuring the COVID-19 effect on clinical trials|
Daniel Chancellor, Thought Leadership and Consulting Director, Informa Pharma Intelligence
|11:00||End of Good Morning Meeting|
|In collaboration with|